“(iii) The rebate amount specified under such paragraph for such part B rebatable drug and calendar quarter.
“(B) Manufacturer requirement.—For each calendar quarter beginning on or after July 1, 2021, the manufacturer of a part B rebatable drug shall, for such drug, not later than 30 days after the date of receipt from the Secretary of the information described in sub-paragraph (A) for such calendar quarter, provide to the Secretary a rebate that is equal to the amount specified in paragraph (3) for such drug for such calendar quarter.
“(2) Part b rebatable drug defined.—
“(A) In general.—In this subsection, the term ‘part B rebatable drug’ means a single source drug or biological (as defined in sub-paragraph (D) of section 184TA(c)(6)), including a biosimilar biological product (as defined in subparagraph (H) of such section), paid for under this part, except such term shall not include such a drug or biological—
“(i) if the average total allowed charges for a year per individual that uses such a drug or biological, as determined by
·HR 4663 TH
